EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Real‐world experience in treatment of donor‐derived Hepatitis C virus in kidney transplant recipients with delayed initiation, shortened course glecaprevir/pibrentasvir versus standard of care

Johanna Papanikolla iD, Melissa McGowan, Mythili Chunduru, Holli Winters, Todd Pesavento, Rachel Smith, Navdeep Singh, Michael Wellner, Lindsay Sobotka, Annelise Nolan

Transplant Infectious Disease · 2024

DOI: 10.1111/tid.14366 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transplant Infectious Disease, 2024. Verfasst von Johanna Papanikolla und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Ohio State University, Columbus, Ohio, USA. Hauptthemen laut MEDLINE: Kidney Transplantation, Antiviral Agents, Sulfonamides, Benzimidazoles. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

There is limited literature describing the real‐world practice of delayed initiation and shortened duration direct‐acting antiviral (DAA) in kidney transplant recipients. We compared Hepatitis C virus (HCV) cure rates among kidney transplant recipients who received an HCV nucleic acid test positive (NAT +) kidney and were treated with sofosbuvir/velpatasvir (SOF/VEL) for 12 weeks or glecaprevir/pibrentasvir (G/P) for 8 weeks, a duration that is 4 weeks shorter than the guideline recommendation for treatment delay beyond 1‐week post‐transplant.

Methods

Retrospective study of HCV‐negative adult patients who received a kidney transplant from an HCV NAT+ donor between April 2019 and April 2022 treated with either SOF/VEL for 12 weeks or G/P for 8 weeks. The primary outcome was sustained virologic response 12 weeks after completion of therapy (SVR12). Secondary outcomes included time to DAA initiation, renal function, graft loss, patient death, liver function tests, and opportunistic infections.

Results

102 kidney transplant recipients were included with 36 treated with G/P and 66 treated with SOF/VEL. All 36 (100%) treated with G/P achieved SVR12. One patient in the SOF/VEL group failed to achieve SVR12 but received additional therapy and was cured. Time to DAA initiation was similar with a mean of 4 weeks. There was no difference in AST/ALT > 3x ULN or renal function. One rejection occurred in each group. No patient death or graft loss was observed. There was no difference in cytomegalovirus and BK viremia between groups.

Conclusion

Delayed initiation of DAA therapy with 12 weeks of SOF/VEL or 8 weeks of G/P achieves SVR12 in kidney transplant recipients without significant adverse effects. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney TransplantationAntiviral AgentsSulfonamidesBenzimidazolesQuinoxalinesHepacivirusPyrrolidinesSofosbuvirSustained Virologic ResponseDrug CombinationsHumansMaleFemaleMiddle AgedRetrospective StudiesTissue DonorsTransplant RecipientsAgedAdultCarbamatesHepatitis CDrug Therapy, CombinationHeterocyclic Compounds, 4 or More RingsLactams, MacrocyclicHepatitis C, ChronicAminoisobutyric AcidsTime-to-Treatment

Stichwörter der Autor:innen

direct‐acting antiviral agentshepatitis Cinfectiouskidney diseasekidney transplantationsustained virologic responseviral

Substanzen

Antiviral AgentsSulfonamidesBenzimidazolesQuinoxalinesPyrrolidinesSofosbuvirDrug Combinationsglecaprevir and pibrentasvirCarbamatesHeterocyclic Compounds, 4 or More Rings

Autor:innen und Institutionen

  • Department of Pharmacy, The Ohio State University, Columbus, Ohio, USA.
  • Department of Pharmacy, TriStar Summit Medical Center, Nashville, Tennessee, USA.
  • Department of Internal Medicine, Nephrology Division, The Ohio State University, Columbus, Ohio, USA.
  • Department of Biomedical Informatics, Center for Biostatistics, The Ohio State University, Columbus, Ohio, USA.
  • Department of Surgery, Transplant Surgery Division, The Ohio State University, Columbus, Ohio, USA.
  • Department of Internal Medicine, Gastroenterology, Hepatology, and Nutrition Division, The Ohio State University, Columbus, Ohio, USA.

ORCID-Profile: Johanna Papanikolla

Zitieren

APA

Papanikolla, J., McGowan, M., Chunduru, M., Winters, H., Pesavento, T., Smith, R., Singh, N., Wellner, M., Sobotka, L., & Nolan, A. (2024). Real‐world experience in treatment of donor‐derived Hepatitis C virus in kidney transplant recipients with delayed initiation, shortened course glecaprevir/pibrentasvir versus standard of care. Transplant Infectious Disease. https://doi.org/10.1111/tid.14366

Vancouver

Papanikolla J, McGowan M, Chunduru M, Winters H, Pesavento T, Smith R, et al. Real‐world experience in treatment of donor‐derived Hepatitis C virus in kidney transplant recipients with delayed initiation, shortened course glecaprevir/pibrentasvir versus standard of care. Transplant Infectious Disease. 2024. doi:10.1111/tid.14366

BibTeX
@article{Papanikolla2024,
  author = {Papanikolla, Johanna and McGowan, Melissa and Chunduru, Mythili and Winters, Holli and Pesavento, Todd and Smith, Rachel and Singh, Navdeep and Wellner, Michael and Sobotka, Lindsay and Nolan, Annelise},
  title = {Real‐world experience in treatment of donor‐derived Hepatitis C virus in kidney transplant recipients with delayed initiation, shortened course glecaprevir/pibrentasvir versus standard of care},
  journal = {Transplant Infectious Disease},
  year = {2024},
  doi = {10.1111/tid.14366}
}
Kostenlos starten →